The story of Sildenafil presents a complex picture for investors. While the initial release generated massive profits, the lapse of its exclusive rights opened the floodgates to off-brand versions, dramatically eroding https://prbookmarkingwebsites.com/story29027348/the-copyright-and-big-pharma-a-risky-opportunity